Investor and Analyst call on GSK’165 aGM-CSF data presented at ACR
On Tuesday, 23 October 2018, Dr Hal Barron, Chief Scientific Officer and President R&D and Luke Miels, President, GSK Global Pharmaceuticals hosted an investor conference call following the presentation of efficacy and safety data on GSK3196165, GSK's anti-GM-CSF antibody in development for Rheumatoid Arthritis at the 2018 American College of Rheumatology (ACR). The call also featured participation from an external expert in rheumatology and GSK’s Medicine Development Lead for GSK’165.